Drugs / ALIA-1758
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06406348 | May 2024 → Apr 2025 | Alzheimer disease | AbbVie | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALIA-1758 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06406348 ↗ |
| Route | Intravenous | “intravenously (IV) or subcutaneously (SC) injected ALIA-1758” NCT06406348 ↗ |
| Route | Subcutaneous | “intravenously (IV) or subcutaneously (SC) injected ALIA-1758” NCT06406348 ↗ |